id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-296556-fr8x8j3i	Chaccour, Carlos	Ivermectin and COVID-19: Keeping Rigor in Times of Urgency	2020-04-16		.txt	text/plain	1400	91	47	10 recently reported that ivermectin is a potent inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. 13 However, even with this dose, which is 10-fold greater than those approved by the US Food and Drug Administration, the C max values reported were ∼250 ng/mL, 13 one order of magnitude lower than effective in vitro concentrations against SARS-CoV-2. Very recently, preliminary findings on a potential effect of hydroxychloroquine combined with azithromycin against SARS-CoV-2 were widely publicized, 15 leading to a surge in demand and self-medication, which resulted in serious harm in some cases and a stock shortage that jeopardized drug availability for other critical conditions for which hydroxychloroquine or chloroquine is the standard of care, that is, vivax malaria, rheumatoid arthritis, and systemic lupus erythematosus. 20, 21 Second, boosted antiretrovirals such as lopinavir/ritonavir and darunavir/cobicistat, which have been widely used against SARS-CoV-2 based on limited evidence, and a number of other drugs, are potent inhibitors of cytochrome P 450 3A4, the main metabolic pathway for ivermectin.	./cache/cord-296556-fr8x8j3i.txt	./txt/cord-296556-fr8x8j3i.txt